Modified bovine G-CSF polypeptides and their uses
View Patent ↗Modified bovine G-CSF polypeptides and uses thereof are provided.
1. A bG-CSF polypeptide comprising the sequence of SEQ ID NO: 2, wherein position 134 of SEQ ID NO: 2 is substituted with a non-naturally encoded amino acid,
wherein the non-naturally encoded amino acid is para-acetylphenylalanine,
wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety,
wherein said water soluble polymer has a molecular weight of about 20 kDa, and
wherein said bG-CSF polypeptide is characterized by inducing a maximal absolute neutrophil count (ANC) about 10-fold greater than pre-treatment ANC, as measured about 72 hours after a single sub-cutaneous injection at 40 μg/kg in a healthy bovine steer calf.
2. A pharmaceutical formulation comprising the bGCSF polypeptide of claim 1 and a pharmaceutically acceptable carrier.
3. A bG-CSF polypeptide comprising the sequence of SEQ ID NO: 2, wherein position 134 of SEQ ID NO: 2 is substituted with a non-naturally encoded amino acid,
wherein the non-naturally encoded amino acid is para-acetylphenylalanine,
wherein the non-naturally encoded amino acid is linked to a water soluble polymer comprising a poly(ethylene) glycol moiety,
wherein said water soluble polymer has a molecular weight of about 20 kDa, and
wherein said bG-CSF polypeptide is characterized by inducing an absolute neutrophil count (ANC) about 7-fold to about 12-fold greater than pre-treatment ANC from about 12 hours to about 96 hours after a single sub-cutaneous injection at 40 μg/kg in a healthy bovine steer calf.
4. A pharmaceutical formulation comprising the bGCSF polypeptide of claim 3 and a pharmaceutically acceptable carrier.